On June 9, 2025, Unicycive Therapeutics, Inc. held its Annual Meeting where stockholders elected four directors, approved the appointment of accountants, and approved a reverse stock split with 78.1 million votes in favor. Approximately 69.7% of shares were voted during the meeting.